Botanee’s $74M Acquisition of Former Shiseido Brands Misses Profit Targets

Botanee Group, the parent company of Chinese clinical skincare giant Winona, recently announced that its subsidiary Hainan Botanee has triggered a performance compensation clause regarding its acquisition of Yuejiang Investment. Because Yuejiang’s cumulative net profit from 2023 to 2025 reached only 102 million RMB ($14.1 million USD)—falling short of the 90% threshold of its 235 million RMB ($32.5 million USD) three-year target—Botanee’s equity stake in Yuejiang will automatically rise from 51% to 69.28%.

While Botanee gained an additional 18.28% stake without spending any extra cash, the domestic market has widely labeled the deal a "failed acquisition."

Why It Matters

For global beauty conglomerates and emerging groups alike, transitioning from a single blockbuster brand to a diversified multi-brand portfolio is a high-stakes journey. Botanee's struggle to revitalize former Shiseido mass-market brands highlights the operational friction that occurs when a high-margin clinical skincare player attempts to manage low-margin, high-turnover mass cosmetics.

A $74 Million Strategic Gamble

On paper, gaining more control of Yuejiang without further cash outlay seems like a win. However, the strategic expectations Botanee set three years ago remain largely unfulfilled.

In September 2023, Hainan Botanee acquired a 48.55% stake in Yuejiang Investment from existing shareholders for 485.5 million RMB and injected an additional 50 million RMB in capital, totaling 535.5 million RMB (approximately $74 million USD) for a controlling 51% stake.

Yuejiang’s portfolio consists of two beauty brands formerly owned by Shiseido: Za, a makeup brand launched in 1997 targeting young women, and Pure&Mild, a mass-market skincare brand Shiseido created in 2001 specifically for Chinese consumers.

Botanee’s willingness to pay $74 million for these divested Shiseido brands stemmed from deep strategic anxiety.

Prior to the acquisition in the first half of 2023, Botanee reported revenues of 2.368 billion RMB across its portfolio, which includes Winona, Winona Baby, AOXMED, and Beforteen. However, Winona alone accounted for over 95% of that revenue.

While rapid growth can temporarily mask the risks of relying on a single brand, the underlying vulnerability never disappears. Global beauty markets have repeatedly proven that investors pay a premium for diversified beauty groups but lose patience with single-brand narratives—a lesson well understood by giants like L'Oréal and Estée Lauder.

Botanee’s market valuation, which peaked at over 120 billion RMB in 2021, plummeted to approximately 14.4 billion RMB by June 2026—an 80% drop. The market’s harsh pricing reflects a persistent skepticism over Botanee’s lack of a viable "second growth engine."

Against this backdrop, the Yuejiang acquisition was an urgent move to diversify. Za was meant to fill Botanee's vacancy in color cosmetics, while Pure&Mild was positioned to capture mass-market skincare consumers below Winona's price point, all while leveraging Yuejiang’s established e-commerce and brand-rebuilding expertise.

As part of the acquisition, Yuejiang's management agreed to an earn-out target, promising net profits of at least 50 million RMB, 80 million RMB, and 105 million RMB for 2023, 2024, and 2025, respectively. This cumulative target of 235 million RMB valued the company at a modest 4.5 times price-to-earnings ratio. But valuation metrics on paper do not guarantee real-world growth.

Ultimately, Yuejiang’s cumulative net profit of 102 million RMB represented just 43.58% of the promised target, with performance dropping sharply year by year.

The Roots of the Mismatch

In a statement to The Economic Observer, Botanee attributed the missed targets to rising supplier costs, a broader slowdown in the cosmetics sector, and soaring customer acquisition costs as e-commerce traffic dividends fade. This shift reflects a broader transition in how trust is redefining China's $140 billion beauty market, where transactional traffic-chasing is giving way to deeper consumer engagement.

While macroeconomic headwinds played a role, the core issue lies in a fundamental operational mismatch between the two companies.

Following the acquisition, Botanee initiated a comprehensive overhaul of Za and Pure&Mild, focusing on product upgrades, brand rejuvenation, and digital operations. On the R&D front, Yuejiang began utilizing the Botanee Research Institute’s plant-extraction technologies and efficacy-testing systems to upgrade its core formulations.

While these steps were strategically sound, Botanee admitted they "impacted short-term profitability but laid the foundation for long-term brand health."

Brand rejuvenation is a slow, capital-intensive process that takes years to yield returns. Demanding immediate, consecutive annual profit growth through an earn-out agreement while simultaneously executing a long-term brand overhaul created a structural conflict. Without rejuvenation, the brands would continue to age; with it, short-term profits were bound to suffer. Ultimately, the financial targets collapsed before the rejuvenation could bear fruit.

Another critical mismatch lies in the business models. Winona’s success is built on premium, dermatological skincare, where heavy R&D, clinical validation, and high-end marketing support high-margin products. Winona boasts a gross margin of 76.31%.

In contrast, Za and Pure&Mild operate in the mass market, with gross margins of 63.28% and 51.3%, respectively. These brands rely on high inventory turnover and cost efficiency. When Botanee attempted to graft its rigorous clinical testing and R&D standards onto these mass-market brands, it inflated their cost structures. Mass-market consumers, who are highly price-sensitive, were unwilling to pay a premium for clinical validation.

The financial toll of this acquisition is clear in Botanee's financial reports. In 2024, the group recorded a goodwill impairment of 91 million RMB and an intangible asset impairment of 25 million RMB for Yuejiang, totaling 116 million RMB. By 2025, Botanee's overall revenue fell 6.58% year-over-year, with net profit virtually flat at 0.53% growth.

What Lies Ahead?

Is this failed earn-out the end of the story?

If judged solely by the financial targets, the acquisition appears to be a failure. However, looking at Botanee's broader corporate trajectory, a different picture emerges.

Under Botanee's stewardship, Za and Pure&Mild achieved explosive volume growth in 2024. Za's revenue surged 420% year-over-year, while Pure&Mild grew 256%, proving that Botanee's channel and operational integration had an immediate impact.

Even as sales cooled in 2025, Za maintained a respectable annual revenue of 452 million RMB, giving it a meaningful scale within Botanee's portfolio, while Pure&Mild contributed 47 million RMB. Crucially, gross margins for both brands improved post-acquisition.

On Tmall, Za's co-branded makeup primer (priced at 65 RMB) has sold over 400,000 units, topping the platform's category charts for 11 consecutive months. This indicates that the brand still holds significant equity among consumers, and its core value remains intact despite short-term financial fluctuations.

Furthermore, Za and Pure&Mild bring a valuable offline footprint. At the time of the 2023 acquisition, the two brands possessed a network of approximately 15,000 offline retail points across the Asia-Pacific region, including major beauty retailers like Watsons, Cosmed, and The Colorist. For Botanee, which historically relies on online channels for over 80% of its revenue, this offline network is highly valuable.

By increasing its stake to 69.28%, Botanee now commands absolute decision-making power. A representative told media outlet Jiemian Fashion that "this gives the group stronger strategic control over Yuejiang, Za, and Pure&Mild, which will streamline decision-making and improve operational efficiency."

Furthermore, Botanee noted that it has been integrating its R&D, sales channels, and international operations since the acquisition. This overseas push aligns with broader regional trends, as seen in how TikTok beauty sales explode in Southeast Asia through localized strategies. From this perspective, the end of the earn-out period might mark the true beginning of deep operational integration.

Meanwhile, Botanee’s core business is showing signs of recovery.

In the fourth quarter of 2025, the company's quarterly revenue rose 10.26% year-over-year to 1.894 billion RMB, while net profit surged 164.87% to 234 million RMB. This momentum carried into the first quarter of 2026, with revenue up 17.84% to 1.118 billion RMB and net profit up 132.76% to 66 million RMB.

Beyond its flagship brand, Botanee's other internal brands are gaining traction. In 2025, its baby care brand, Winona Baby, grew 17.02% to 2.35 million RMB, while its premium anti-aging brand, AOXMED, surged 115.1% to 129 million RMB.

These figures suggest that Botanee’s multi-brand strategy—combining strategic acquisitions with in-house incubation—is starting to prove its viability.

The transition from a single-brand success story to a diversified global beauty group is always fraught with trial and error, but it remains an inevitable path for China's leading cosmetics players. Botanee's journey serves as a compelling case study. The setback of a three-year earn-out may simply be the opening chapter of a much larger transformation.

From July 1–3, 2026, the 2026 iPDF International Future Packaging Exhibition will open at the Guangzhou Airport Expo Center. The event will feature the 3rd Beauty Cross-Border Export Conference, offering dedicated sessions on South Korea, Indonesia, and the U.S. markets, alongside deep dives into overseas compliance, localized marketing, product selection, and global supply chain integration.